Global acute myeloid leukemia diagnostics market is projected to register a substantial CAGR of 11.3% in the forecast period of 2024 to 2031. The new market report contains data for the historic year 2022, the base year of calculation is 2022, and the forecast period is 2024 to 2031.
Market Segmentation
Global Acute Myeloid Leukemia Diagnostics Market, By Product Type (Instruments, and Consumables & Accessories), Test Type (Imaging Test, Blood Test, Bone Marrow Test, Biomarker Test, Immunophenotyping, Genetic Testing and Others), Cancer Type (Myeloblastic (M0), Myeloblastic (M1), Myeloblastic (M2), Promyelocytic (M3), Myelomonocytic (M4), MONOCYTIC (M5), Erythroleukemia (M6) and Megakaryocytic (M7)), Age Group (Below 21, 21-29, 30-65, 65, and Above), Gender (Male and Female) End User (Hospital, Associated Labs, Independent Diagnostic Laboratories, Diagnostic Imaging Centers, Cancer Research Institutes, and Others), Distribution Channel (Direct Tender, Retail Sales), Country ( U.S., Canada, Mexico, Germany, France, U.K., Italy, Spain, Netherlands, Russia, Switzerland, Turkey, Belgium, Rest of Europe, China, Japan, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, Vietnam, Rest Of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, U.A.E., Egypt, Israel, Rest of Middle East and Africa) - Industry Trends and Forecast to 2031.
Driver
Increasing diagnostic products for leukemia cancer
Restraint
Late diagnosis and Poor prognosis of leukemia
Opportunity
Initiatives by government and other authorities for life sciences and funding
Market Players
Some of the major market players in the global acute myeloid leukemia diagnostics market are:
- F. Hoffmann-La Roche Ltd.
- Thermo Fisher Scientific, Inc.
- QIAGEN
- Abbott
- Siemens Healthcare GmbH
- Hologic, Inc.
- Agilent Technologies, Inc.
- DiaSorin S.p.A.
- Illumina, Inc.
- BIOMERIEUX
- Myriad Genetics, Inc.
- Quest Diagnostics Incorporated.
- Bio-Rad Laboratories, Inc.
- Koninklijke Philips N.V.
- BD
- Exact Sciences Corporation
- Time Medical Holding
- PlexBio
- MinFound Medical Systems Co., Ltd
- Medonica Co. LTD
- CANON MEDICAL SYSTEMS CORPORATION
- Sysmex Corporation
- Epigenomics AG
- Sonic Healthcare
- SternMed GmbH
TABLE OF CONTENTS
1 INTRODUCTION 53
- 1.1 OBJECTIVES OF THE STUDY 53
- 1.2 MARKET DEFINITION 53
- 1.3 OVERVIEW OF THE GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET 53
- 1.4 LIMITATIONS 55
- 1.5 MARKETS COVERED 56
2 MARKET SEGMENTATION 59
- 2.1 MARKETS COVERED 59
- 2.2 GEOGRAPHICAL SCOPE 60
- 2.3 YEARS CONSIDERED FOR THE STUDY 61
- 2.4 CURRENCY AND PRICING 61
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 62
- 2.6 MULTIVARIATE MODELLING 65
- 2.7 PRODUCT TYPE LIFELINE CURVE 65
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 66
- 2.9 DBMR MARKET POSITION GRID 67
- 2.10 MARKET END USER COVERAGE GRID 68
- 2.11 VENDOR SHARE ANALYSIS 69
- 2.12 SECONDARY SOURCES 70
- 2.13 ASSUMPTIONS 70
3 EXECUTIVE SUMMARY 71
4 PREMIUM INSIGHTS 74
- 4.1 PESTEL ANALYSIS 77
- 4.2 PORTER'S FIVE FORCES 78
- 4.3 EPIDEMIOLOGY 79
5 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, REGULATIONS 80
- 5.1 REGULATORY SCENARIO IN THE U.S. 80
- 5.2 REGULATORY SCENARIO IN AUSTRALIA 81
- 5.3 REGULATORY SCENARIO IN JAPAN 81
- 5.4 REGULATORY SCENARIO IN CHINA 81
6 MARKET OVERVIEW 83
- 6.1 DRIVERS 85
- 6.1.1 GROWING PREVALENCE OF LEUKEMIA CANCER 85
- 6.1.2 NOVEL TECHNOLOGICAL ADVANCEMENTS IN LEUKEMIA DIAGNOSTICS 87
- 6.1.3 RISING PREFERENCE FOR PREVENTIVE HEALTH CHECK-UPS 87
- 6.1.4 INCREASE IN AWARENESS REGARDING LEUKEMIA CANCER 88
- 6.2 RESTRAINTS 88
- 6.2.1 STRICT REGULATIONS AND STANDARDS FOR THE APPROVAL AND COMMERCIALIZATION OF LEUKEMIA DIAGNOSTIC PRODUCTS 88
- 6.2.2 LATE DIAGNOSIS AND POOR PROGNOSIS OF LEUKEMIA 89
- 6.3 OPPORTUNITIES 89
- 6.3.1 INCREASE IN DIAGNOSTIC PRODUCTS FOR LEUKEMIA 89
- 6.3.2 RISE IN HEALTHCARE EXPENDITURE FOR CANCER DIAGNOSIS AND TREATMENT 90
- 6.3.3 GOVERNMENT INITIATIVES TOWARD CANCER DIAGNOSTICS 91
- 6.4 CHALLENGES 91
- 6.4.1 INCREASED COST, SAFETY, AND CONVENIENCE ISSUES 91
- 6.4.2 LACK OF SKILLED AND CERTIFIED PROFESSIONALS 92
7 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY PRODUCT TYPE 93
- 7.1 OVERVIEW 94
- 7.2 INSTRUMENTS 97
- 7.2.1 BIOPSY INSTRUMENTS 98
- 7.2.1.1 BONE MARROW BIOPSY 98
- 7.2.1.2 NEEDLE BIOPSY 98
- 7.2.1.3 SURGICAL BIOPSY 98
- 7.2.1.4 OTHERS 98
- 7.2.2 PATHOLOGY-BASED INSTRUMENTS 99
- 7.2.2.1 PCR INSTRUMENTS 99
- 7.2.2.2 SLIDE STAINING SYSTEMS 99
- 7.2.2.3 TISSUE PROCESSING SYSTEMS 99
- 7.2.2.4 CELL PROCESSORS 99
- 7.2.2.5 OTHER PATHOLOGY-BASED INSTRUMENTS 99
- 7.2.3 IMAGING INSTRUMENTS 100
- 7.2.3.1 ULTRASOUND SYSTEMS 100
- 7.2.3.2 CT SYSTEMS 100
- 7.2.3.3 MRI SYSTEMS 100
- 7.2.3.4 OTHERS 100
- 7.2.4 OTHERS 100
- 7.3 CONSUMABLES & ACCESSORIES 101
- 7.3.1 KITS 102
- 7.3.1.1 PCR KITS 102
- 7.3.1.2 DNA POLYMERASE KITS 102
- 7.3.1.3 NUCLEIC ACID ISOLATION KITS 102
- 7.3.1.4 OTHERS 102
- 7.3.2 REAGENTS 103
- 7.3.2.1 ASSAYS 103
- 7.3.2.2 BUFFERS 103
- 7.3.2.3 PRIMERS 103
- 7.3.2.4 OTHERS 103
- 7.3.3 PROBES 104
- 7.3.4 OTHER CONSUMABLES 104
8 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY TEST TYPE 105
- 8.1 OVERVIEW 106
- 8.2 BLOOD TEST 109
- 8.2.1 COMPLETE BLOOD COUNT (CBC) 110
- 8.2.2 BLOOD CHEMISTRY TESTS 110
- 8.2.3 OTHERS 110
- 8.3 IMAGING TEST 111
- 8.3.1 COMPUTED TOMOGRAPHY (CT) SCAN 111
- 8.3.2 MRI 111
- 8.3.3 POSITRON EMISSION TOMOGRAPHY (PET) SCAN 112
- 8.3.4 OTHERS 112
- 8.4 BONE MARROW TESTS 112
- 8.4.1 BONE MARROW ASPIRATE 113
- 8.4.2 BONE MARROW BIOPSY 113
- 8.4.3 OTHERS 113
- 8.5 GENETIC TESTS 113
- 8.5.1 FLUORESCENCE IN SITU HYBRIDIZATION (FISH) 114
- 8.5.2 KARYOTYPING 114
- 8.5.3 OTHERS 114
- 8.6 BIOMARKER TEST 115
- 8.6.1 GENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 115
- 8.6.2 EPIGENETIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 115
- 8.6.3 PROTEOMIC ACUTE MYELOID LEUKEMIA (AML) BIOMARKER 116
- 8.7 IMMUNOPHENOTYPING 116
- 8.7.1 FLOW CYTOMETRY 116
- 8.7.2 IMMUNOHISTOCHEMISTRY 117
- 8.7.3 OTHERS 117
- 8.8 OTHERS 117
9 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY CANCER TYPE 118
- 9.1 OVERVIEW 119
- 9.2 MYELOBLASTIC (M0) 122
- 9.3 MYELOBLASTIC (M1) 123
- 9.4 MYELOBLASTIC (M2) 123
- 9.5 PROMYELOCYTIC (M3) 124
- 9.6 MYELOMONOCYTIC (M4) 124
- 9.7 MONOCYTIC (M5) 125
- 9.8 ERYTHROLEUKEMIA (M6) 125
- 9.9 MEGAKARYOCYTIC (M7) 126
10 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY AGE GROUP 127
- 10.1 OVERVIEW 128
- 10.2 65 AND ABOVE 131
- 10.3 30-65 132
- 10.4 BELOW 21 132
- 10.5 21-29 133
11 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY GENDER 134
- 11.1 OVERVIEW 135
- 11.2 MALE 138
- 11.3 FEMALE 139
12 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY END USER 140
- 12.1 OVERVIEW 141
- 12.2 HOSPITALS 144
- 12.3 ASSOCIATED LABS 145
- 12.4 INDEPENDENT DIAGNOSTIC LABORATORIES 145
- 12.5 DIAGNOSTIC IMAGING CENTERS 146
- 12.6 CANCER RESEARCH INSTITUTES 146
- 12.7 OTHERS 147
13 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY DISTRIBUTION CHANNEL 148
- 13.1 OVERVIEW 149
- 13.2 DIRECT TENDER 152
- 13.3 RETAIL SALES 153
14 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET, BY REGION 154
- 14.1 OVERVIEW 155
- 14.2 NORTH AMERICA 159
- 14.2.1 U.S. 165
- 14.2.2 CANADA 170
- 14.2.3 MEXICO 175
- 14.3 EUROPE 180
- 14.3.1 GERMANY 186
- 14.3.2 UNITED KINGDOM 191
- 14.3.3 FRANCE 196
- 14.3.4 ITALY 201
- 14.3.5 SPAIN 206
- 14.3.6 RUSSIA 211
- 14.3.7 NETHERLANDS 216
- 14.3.8 SWITZERLAND 221
- 14.3.9 BELGIUM 226
- 14.3.10 TURKEY 231
- 14.3.11 REST OF EUROPE 236
- 14.4 ASIA-PACIFIC 237
- 14.4.1 CHINA 243
- 14.4.2 JAPAN 248
- 14.4.3 INDIA 253
- 14.4.4 AUSTRALIA 258
- 14.4.5 SOUTH KOREA 263
- 14.4.6 INDONESIA 268
- 14.4.7 PHILIPPINES 273
- 14.4.8 THAILAND 278
- 14.4.9 MALAYSIA 283
- 14.4.10 VIETNAM 288
- 14.4.11 SINGAPORE 294
- 14.4.12 REST OF ASIA-PACIFIC 299
- 14.5 SOUTH AMERICA 300
- 14.5.1 BRAZIL 306
- 14.5.2 ARGENTINA 311
- 14.5.3 REST OF SOUTH AMERICA 316
- 14.6 MIDDLE EAST AND AFRICA 317
- 14.6.1 SOUTH AFRICA 323
- 14.6.2 SAUDI ARABIA 328
- 14.6.3 U.A.E 333
- 14.6.4 EGYPT 338
- 14.6.5 ISRAEL 343
- 14.6.6 REST OF MIDDLE EAST AND AFRICA 348
15 GLOBAL ACUTE MYELOID LEUKEMIA DIAGNOSTICS MARKET: COMPANY LANDSCAPE 349
- 15.1 COMPANY SHARE ANALYSIS: GLOBAL 349
- 15.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 350
- 15.3 COMPANY SHARE ANALYSIS: EUROPE 351
- 15.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 352
16 SWOT ANALYSIS 353
17 COMPANY PROFILES 354
- 17.1 CANON MEDICAL SYSTEMS CORPORATION. 354
- 17.1.1 COMPANY SNAPSHOT 354
- 17.1.2 REVENUE ANALYSIS 355
- 17.1.3 COMPANY SHARE ANALYSIS 355
- 17.1.4 PRODUCT PORTFOLIO 356
- 17.1.5 RECENT DEVELOPMENT 356
- 17.2 SYSMEX CORPORATION 357
- 17.2.1 COMPANY SNAPSHOT 357
- 17.2.2 REVENUE ANALYSIS 357
- 17.2.3 COMPANY SHARE ANALYSIS 358
- 17.2.4 PRODUCT PORTFOLIO 358
- 17.2.5 RECENT DEVELOPMENT 358
- 17.3 EPIGENOMICS AG. 359
- 17.3.1 COMPANY SNAPSHOT 359
- 17.3.2 REVENUE ANALYSIS 359
- 17.3.3 COMPANY SHARE ANALYSIS 360
- 17.3.4 PRODUCT PORTFOLIO 360
- 17.3.5 RECENT DEVELOPMENT 361
- 17.4 MYRIAD GENETICS, INC. 362
- 17.4.1 COMPANY SNAPSHOT 362
- 17.4.2 REVENUE ANALYSIS 362
- 17.4.3 COMPANY SHARE ANALYSIS 363
- 17.4.4 PRODUCT PORTFOLIO 363
- 17.4.5 RECENT DEVELOPMENT 364
- 17.5 F. HOFFMANN- LA ROCHE LTD 365
- 17.5.1 COMPANY SNAPSHOT 365
- 17.5.2 REVENUE ANALYSIS 365
- 17.5.3 COMPANY SHARE ANALYSIS 366
- 17.5.4 PRODUCT PORTFOLIO 366
- 17.5.5 RECENT DEVELOPMENT 366
- 17.6 ABBOTT 367
- 17.6.1 COMPANY SNAPSHOT 367
- 17.6.2 REVENUE ANALYSIS 367
- 17.6.3 PRODUCT PORTFOLIO 368
- 17.6.4 RECENT DEVELOPMENT 368
- 17.7 AGILENT TECHNOLOGIES, INC. 369
- 17.7.1 COMPANY SNAPSHOT 369
- 17.7.2 REVENUE ANALYSIS 369
- 17.7.3 PRODUCT PORTFOLIO 370
- 17.7.4 RECENT DEVELOPMENT 370
- 17.8 BD 371
- 17.8.1 COMPANY SNAPSHOT 371
- 17.8.2 REVENUE ANALYSIS 371
- 17.8.3 PRODUCT PORTFOLIO 372
- 17.8.4 RECENT DEVELOPMENT 372
- 17.9 BIOMERIEUX 373
- 17.9.1 COMPANY SNAPSHOT 373
- 17.9.2 PRODUCT PORTFOLIO 373
- 17.9.3 RECENT DEVELOPMENT 373
- 17.10 BIO-RAD LABORATORIES, INC. 374
- 17.10.1 COMPANY SNAPSHOT 374
- 17.10.2 REVENUE ANALYSIS 374
- 17.10.3 PRODUCT PORTFOLIO 375
- 17.10.4 RECENT DEVELOPMENT 375
- 17.11 DIASORIN S.P.A. 376
- 17.11.1 COMPANY SNAPSHOT 376
- 17.11.2 REVENUE ANALYSIS 376
- 17.11.3 PRODUCT PORTFOLIO 377
- 17.11.4 RECENT DEVELOPMENTS 377
- 17.12 EXACT SCIENCES CORPORATION 378
- 17.12.1 COMPANY SNAPSHOT 378
- 17.12.2 REVENUE ANALYSIS 378
- 17.12.3 PRODUCT PORTFOLIO 379
- 17.12.4 RECENT DEVELOPMENTS 379
- 17.13 HOLOGIC INC. 380
- 17.13.1 COMPANY SNAPSHOT 380
- 17.13.2 REVENUE ANALYSIS 380
- 17.13.3 PRODUCT PORTFOLIO 381
- 17.13.4 RECENT DEVELOPMENT 381
- 17.14 ILLUMINA, INC. 382
- 17.14.1 COMPANY SNAPSHOT 382
- 17.14.2 REVENUE ANALYSIS 382
- 17.14.3 PRODUCT PORTFOLIO 383
- 17.14.4 RECENT DEVELOPMENT 383
- 17.15 KONINKLIJKE PHILIPS N.V. 384
- 17.15.1 COMPANY SNAPSHOT 384
- 17.15.2 REVENUE ANALYSIS 384
- 17.15.3 PRODUCT PORTFOLIO 385
- 17.15.4 RECENT DEVELOPMENT 385
- 17.16 MEDONICA CO. LTD 386
- 17.16.1 COMPANY SNAPSHOT 386
- 17.16.2 PRODUCT PORTFOLIO 386
- 17.16.3 RECENT DEVELOPMENT 386
- 17.17 MINFOUND MEDICAL SYSTEMS CO., LTD 387
- 17.17.1 COMPANY SNAPSHOT 387
- 17.17.2 PRODUCT PORTFOLIO 387
- 17.17.3 RECENT DEVELOPMENT 388
- 17.18 PLEXBIO 389
- 17.18.1 COMPANY SNAPSHOT 389
- 17.18.2 PRODUCT PORTFOLIO 389
- 17.18.3 RECENT DEVELOPMENTS 389
- 17.19 QIAGEN 390
- 17.19.1 COMPANY SNAPSHOT 390
- 17.19.2 REVENUE ANALYSIS 390
- 17.19.3 PRODUCT PORTFOLIO 391
- 17.19.4 RECENT DEVELOPMENTS 391
- 17.20 QUEST DIAGNOSTICS INCORPORATED 392
- 17.20.1 COMPANY SNAPSHOT 392
- 17.20.2 REVENUE ANALYSIS 392
- 17.20.3 PRODUCT PORTFOLIO 393
- 17.20.4 RECENT DEVELOPMENTS 393
- 17.21 SIEMENS HEALTHCARE GMBH 394
- 17.21.1 COMPANY SNAPSHOT 394
- 17.21.2 REVENUE ANALYSIS 394
- 17.21.3 PRODUCT PORTFOLIO 395
- 17.21.4 RECENT DEVELOPMENT 395
- 17.22 SONIC HEALTHCARE 396
- 17.22.1 COMPANY SNAPSHOT 396
- 17.22.2 PRODUCT PORTFOLIO 396
- 17.22.3 RECENT DEVELOPMENT 396
- 17.23 STERNMED GMBH 397
- 17.23.1 COMPANY SNAPSHOT 397
- 17.23.2 PRODUCT PORTFOLIO 397
- 17.23.3 RECENT DEVELOPMENTS 397
- 17.24 THERMO FISHER SCIENTIFIC INC. 398
- 17.24.1 COMPANY SNAPSHOT 398
- 17.24.2 REVENUE ANALYSIS 398
- 17.24.3 PRODUCT PORTFOLIO 399
- 17.24.4 RECENT DEVELOPMENT 399
- 17.25 TIME MEDICAL HOLDING 400
- 17.25.1 COMPANY SNAPSHOT 400
- 17.25.2 PRODUCT PORTFOLIO 400
- 17.25.3 RECENT DEVELOPMENT 401
18 QUESTIONNAIRE 402
19 RELATED REPORTS 406